These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1664127)

  • 21. Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection.
    Kumaraguru U; Gierynska M; Norman S; Bruce BD; Rouse BT
    J Virol; 2002 Jan; 76(1):136-41. PubMed ID: 11739679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abundant expression of herpes simplex virus glycoprotein gB using an adenovirus vector.
    Johnson DC; Ghosh-Choudhury G; Smiley JR; Fallis L; Graham FL
    Virology; 1988 May; 164(1):1-14. PubMed ID: 2834864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isogenic adenoviruses type 5 expressing or not expressing the E1A gene: efficiency as virus vectors in the vaccination of permissive and non-permissive species.
    Eloit M; Adam M
    J Gen Virol; 1995 Jul; 76 ( Pt 7)():1583-9. PubMed ID: 9049365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant vaccinia virus expressing the herpes simplex virus type 1 glycoprotein C protects mice against herpes simplex virus challenge.
    Weir JP; Bennett M; Allen EM; Elkins KL; Martin S; Rouse BT
    J Gen Virol; 1989 Oct; 70 ( Pt 10)():2587-94. PubMed ID: 2794972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1.
    Papp Z; Babiuk LA; Baca-Estrada ME
    Vaccine; 1999 Feb; 17(7-8):933-43. PubMed ID: 10067700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The proportion of herpes simplex virus-specific cytotoxic T lymphocytes (Tc) that recognize glycoprotein C varies between individual mice and is dependent on the form of immunization.
    Martin S; Mercadal CM; Weir JP; Rouse BT
    Viral Immunol; 1993; 6(1):21-33. PubMed ID: 8386515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of oral administration of live herpes simplex virus type 1 as a vaccine.
    Irie H; Harada Y; Kataoka M; Nagamuta M; Moriya Y; Handa M; Saito M; Matsubara S; Kojima K; Sugawara Y
    J Virol; 1992 Apr; 66(4):2428-34. PubMed ID: 1312638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD.
    Zarling JM; Moran PA; Burke RL; Pachl C; Berman PW; Lasky LA
    J Immunol; 1986 Jun; 136(12):4669-73. PubMed ID: 2423598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and characterization of baculovirus expressed herpes simplex virus type 1 glycoprotein L.
    Ghiasi H; Kaiwar R; Slanina S; Nesburn AB; Wechsler SL
    Arch Virol; 1994; 138(3-4):199-212. PubMed ID: 7998829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins.
    Nass PH; Elkins KL; Weir JP
    J Infect Dis; 1998 Sep; 178(3):611-7. PubMed ID: 9728527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector.
    Manservigi R; Grossi MP; Gualandri R; Balboni PG; Marchini A; Rotola A; Rimessi P; Di Luca D; Cassai E; Barbanti-Brodano G
    J Virol; 1990 Jan; 64(1):431-6. PubMed ID: 2152829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospects for vaccines for herpes simplex viruses.
    Berman PW
    J Am Acad Dermatol; 1988 Jan; 18(1 Pt 2):226-30. PubMed ID: 2828443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetically engineered herpes simplex virus vaccines.
    Watson RJ; Enquist LW
    Prog Med Virol; 1985; 31():84-108. PubMed ID: 2982176
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
    Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
    Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity.
    Allen EM; Weir JP; Martin S; Mercadal C; Rouse BT
    Viral Immunol; 1990; 3(3):207-15. PubMed ID: 2175194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
    Malherbe DC; Mendy J; Vang L; Barnette PT; Reed J; Lakhashe SK; Owuor J; Gach JS; Legasse AW; Axthelm MK; LaBranche CC; Montefiori D; Forthal DN; Park B; Wilson JM; McLinden JH; Xiang J; Stapleton JT; Sacha JB; Haynes BF; Liao HX; Ruprecht RM; Smith J; Gurwith M; Haigwood NL; Alexander J
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of T cell responses to glycoprotein B (gB-1) of herpes simplex virus type 1 and its non-glycosylated precursor protein, pgB-1.
    O'Donnell CA; Chan WL
    Clin Exp Immunol; 1991 Oct; 86(1):30-6. PubMed ID: 1655317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector.
    Hariharan MJ; Driver DA; Townsend K; Brumm D; Polo JM; Belli BA; Catton DJ; Hsu D; Mittelstaedt D; McCormack JE; Karavodin L; Dubensky TW; Chang SM; Banks TA
    J Virol; 1998 Feb; 72(2):950-8. PubMed ID: 9444987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.
    Farrell HE; McLean CS; Harley C; Efstathiou S; Inglis S; Minson AC
    J Virol; 1994 Feb; 68(2):927-32. PubMed ID: 8289395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.